Abstract: Pan-genotypic HCV inhibitors are described. This invention also relates to methods of using these inhibitors to treat HCV infection.

Abstract: Novel double-stranded RNA oligonucleotides are useful for decreasing tyrosinase expression, have cosmetic and/or pharmaceutical applications, for example are useful skin depigmenting or anti-browning agents, and can be associated with cationic particles less than or equal to 1 ?m in size, having a zeta potential of from 10 to 80 mV.

Abstract: Method and system to centrally monitor the quality of images of financial documents. Embodiments of the present invention can provide a way to monitor and evaluate the quality of images of financial documents stored for remote access by financial institutions. In some embodiments, a standard quality analysis of at least some of the images is performed, and, based on the quality analysis, suspect images are identified to a responsible entity. For at least some of the images, a decisioning result from the responsible entity is recorded in association with information identifying the images. The quality analysis can be applied based on exclusion criteria such as an amount threshold, certain routing information, etc. The suspect images can be identified by sending a quality results file to the responsible entity, and a decisioning result can be received in a decisioning results file.

Abstract: Expression of a messenger RNA which encodes a protein which is expressed by differentiated cells, notably the cells of the skin or appendages thereof, is inhibited by topically administering to said differentiated cells a thus effective amount of at least one double-stranded RNA oligonucleotide, formulated into a topically applicable, physiologically acceptable medium therefor; such regime or regimen is useful for treating a variety of afflictions or conditions, e.g., combating the signs of skin aging, stimulating hair growth or retarding loss thereof, inhibiting cellular proliferation and/or differentiation, etc.

Abstract: Novel double-stranded RNA oligonucleotides are useful for decreasing tyrosinase expression, have cosmetic and/or pharmaceutical applications, for example are useful skin depigmenting or anti-browning agents, and can be associated with cationic particles less than or equal to 1 ?m in size, having a zeta potential of from 10 to 80 mV.

Abstract: A protective glove/wrist guard device is provided that prevents hands from slipping out from under a falling ice skater when the ice skater extends his or her hands to break a fall. The protective glove/wrist guard device may include a palm surface portion having a high-friction surface portion, to provide both high-friction when contacting ice, and wrist support to help prevent wrist and hand injuries. Alternatively, the protective device may be in the form of a glove with a high friction material disposed on a palm surface portion of the glove.

Abstract: Novel double-stranded RNA oligonucleotides are useful for decreasing tyrosinase expression, have cosmetic and/or pharmaceutical applications, for example are useful skin depigmenting or anti-browning agents, and can be associated with cationic particles less than or equal to 1 ?m in size, having a zeta potential of from 10 to 80 mV.

Abstract: Method and system to centrally monitor the quality of images of financial documents. Embodiments of the present invention can provide a way to monitor and evaluate the quality of images of financial documents stored for remote access by financial institutions. In some embodiments, a standard quality analysis of at least some of the images is performed, and, based on the quality analysis, suspect images are identified to a responsible entity. For at least some of the images, a decisioning result from the responsible entity is recorded in association with information identifying the images. The quality analysis can be applied based on exclusion criteria such as an amount threshold, certain routing information, etc. The suspect images can be identified by sending a quality results file to the responsible entity, and a decisioning result can be received in a decisioning results file.

Abstract: The present invention relates to vectorization of double stranded RNA oligonucleotides by cationic particles chosen from among surfactant micelles, block or non-block polymer micelles, cationic liposomes and niosomes, cationic oleosomes and cationic nanoemulsions, as well as from among cationic organic or inorganic particles and nanocapsules, and to the use of compositions comprising the association of at least one dsRNA and at least one cationic particle on skin models.

Abstract: The present invention relates to vectorization of double stranded RNA oligonucleotides by cationic particles chosen from among surfactant micelles, block or non-block polymer micelles, cationic liposomes and niosomes, cationic oleosomes and cationic nanoemulsions, as well as from among cationic organic or inorganic particles and nanocapsules, and topical compositions for the skin, mucous membranes or eyes.

Abstract: The subject invention relates to monoclonal antibodies that have the ability to bolster the function of the GLP-1 receptor and may therefore have utility in the treatment of mammalian metabolic disorders such as, for example, diabetes. In particular, the invention describes the generation of fully human monoclonal antibodies made against extracellular domains of the human GLP-1 receptor which are capable of binding the intact receptor and activating it in a manner similar to the native ligand. Additionally, the invention describes methods used to generate and develop allosteric modulator antibodies of the human GLP-1 receptor with potential therapeutic uses.

Abstract: The present invention is directed to preferred pharmaceutical compositions comprising sibutramine and rimonabant and use of sibutramine and rimonabant to treat obesity and obesity related disorders in a patient.

Abstract: The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.

Abstract: The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.

Abstract: The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, which antagonize the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor and are useful for the prevention or treatment of eating disorders, weight gain and obesity.

Abstract: The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.

Abstract: Expression of a messenger RNA which encodes a protein which is expressed by differentiated cells, notably the cells of the skin or appendages thereof, is inhibited by topically administering to said differentiated cells a thus effective amount of at least one double-stranded RNA oligonucleotide, formulated into a topically applicable, physiologically acceptable medium therefor; such regime or regimen is useful for treating a variety of afflictions or conditions, e.g., combating the signs of skin aging, stimulating hair growth or retarding loss thereof, inhibiting cellular proliferation and/or differentiation, etc.

Abstract: The present invention is directed to compounds of formula (I), which antagonize of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.

Abstract: The present invention is directed to compounds of formula (I), which antagonize of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.

Abstract: The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.